Log in  First Connection?
  
EnglishJapaneseFrenchSpanishGerman

Others Urological ConditionsArchives

Efficacy and safety of gepotidacin versus standard of-care antibiotics for the treatment of uncomplicated urogenital infections in adults and adolescents: a systematic review and meta-analysis
Others Urological Conditions
 1 min.

 Published on 15/05/2026 |  Original article (Full-text)  | Mounika Reddy et al. | Expert Review of Anti-infective Therapy 2026; 24(4): 425-34

Gepotidacin, a novel oral antibacterial targeting bacterial DNA gyrase and topoisomerase IV, exhibits potent activity against Escherichia coli and Neisseria gonorrhoeae resistant strains. This systematic review and meta-analysis assessed the efficacy and safety of gepotidacin compared with standard-of-care...

HTML version PDF version  Print abstract

Clinical utility of cell-free urine miR-93-5p, miR-191-5p, miR-31-5p for invasive urothelial carcinoma detection and immune signature-based subtyping
Others Urological Conditions
 6 min.

 Published on 08/05/2026 |  Original article (Full-text)  | Özden Sami Berk et al. | BMC Urology 2026; 26(1): 41

Urothelial carcinoma (UC) is a significant global health concern, ranking as the ninth most common malignancy worldwide and one of the leading causes of mortality among urological cancers [1]. Representing the predominant histological subtype of bladder cancer, UC is characterized by marked biological...

HTML version PDF version  Print abstract

Comparative outcomes of distal ureterectomy vs. radical nephroureterectomy in high-risk distal ureteral urothelial carcinoma: a two-center cohort study in Northern and Southern China
Others Urological Conditions
 5 min.

 Published on 01/05/2026 |  Original article (Full-text)  | Xie Junyi et al. | BMC Medicine 2026; 24(1): 88

High-risk distal ureteral urothelial carcinoma (UC) is an aggressive malignancy in the lower ureter, known for its potential for local invasion and distant metastasis. Prompt and appropriate surgical intervention is crucial to improving patient outcomes and survival. Among the surgical options for treating...

HTML version PDF version  Print abstract

MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers
Others Urological Conditions
 1 min.

 Published on 24/04/2026 |  Original article (Full-text)  | Panagiotis J. Vlachostergios et al. | Immunotherapy 2026; 18(2): 99-116

Immune checkpoint inhibitors (ICIs) have significantly transformed the treatment landscape of urologic malignancies, including bladder cancer, renal cell carcinoma (RCC), and prostate cancer. Despite impressive clinical responses in subsets of patients, the heterogeneity of response highlights the urgent...

HTML version PDF version  Print abstract

Successful Management of Immune-Related Cardiac Adverse Events and Long-term Survival in a Patient with Metastatic Urothelial Carcinoma Treated with Tislelizumab: A Case Report
Others Urological Conditions
 1 min.

 Published on 17/04/2026 |  Original article (Full-text)  | Huiguang Gao et al. | European Heart Journal Supplement. Volume 28(Supplement 2).

Urothelial carcinoma is the most common pathological type of bladder tumor, accounting for approximately 90% of all primary bladder malignancies. Locally advanced or metastatic urothelial carcinoma is generally difficult to cure, and treatment options remain limited. PD-1/PD-L1 immune checkpoint inhibitors...

HTML version PDF version  Print abstract